The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Dorofeev D.A.

Regional clinical hospital No 3

Kirilik E.V.

Polyclinic No 1 of the City Clinical Hospital No. 2

Klimova A.V.

South Ural State Medical University

Solovieva A.B.

GEROPHARM LLC

Effect of retinal protective therapy on optical coherence tomography angiography (pilot study)

Authors:

Dorofeev D.A., Kirilik E.V., Klimova A.V., Solovieva A.B.

More about the authors

Journal: Russian Annals of Ophthalmology. 2021;137(1): 60‑67

Read: 1898 times


To cite this article:

Dorofeev DA, Kirilik EV, Klimova AV, Solovieva AB. Effect of retinal protective therapy on optical coherence tomography angiography (pilot study). Russian Annals of Ophthalmology. 2021;137(1):60‑67. (In Russ.)
https://doi.org/10.17116/oftalma202113701160

Recommended articles:
Electrophysiological methods in the diagnosis and moni­toring of glaucoma. Russian Annals of Ophthalmology. 2025;(4):102-109
Modern devi­ces for microinvasive glaucoma surgery. Russian Annals of Ophthalmology. 2025;(5):101-108
Neuroprotective therapy in adva­nced primary open-angle glaucoma. Russian Annals of Ophthalmology. 2025;(6):75-80
The known and new ideas about the mechanism of action and the spectrum of effe­cts of Mexi­dol. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5):22-33
Therapeutic pote­ntial of quercetin and its deri­vatives against COVID-19. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5):44-50

References:

  1. Nesterov AP. Glaucoma. M.: Medicina; 1995. (In Russ.).
  2. Quigley H, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006;90(3):262-267.  https://doi.org/10.1136/bjo.2005.081224
  3. Flaxman SR, Bourne RA, Resnikoff S, et al. Global causes of blindness and distance vision impairment 1990—2020: a systematic review and meta-analysis. Lancet Glob Heal. 2017;5(12):1221-1234. https://doi.org/10.1016/s2214-109x(17)30393-5
  4. Osborne NN, Chidlow G, Wood J, Casson R. Some current ideas on the pathogenesis and the role of neuroprotection in glaucomatous optic neuropathy. Eur J Ophthalmol. 2003;13(suppl 3):19-26.  https://doi.org/10.1177/112067210301303s04
  5. Avdeev RV, Aleksandrov AS, Basinskii AS, et al. A clinical and epidemiological study of risk factors of glaucoma development and progression. Rossiyskiy oftal’mologicheskiy zhurnal = Russian Ophthalmological Journal. 2013; 6(3):4-11. (In Russ.).
  6. Gorodnichii VV, Dorofeev DA, Zavadskii PC, et al. Risk factors, pathogenic factors in progression of glaucoma by results of multicenter study of Russian glaucoma society. Mediko-biologicheskiye problemy zhiznedeyatel’nosti = Medical and Biological Problems of life Activity. 2012;8(2):57-69. (In Russ.).
  7. Avdeev RV, Alexandrov AS, Bakunina NA, et al. A model of primary open-angle glaucoma: manifestations and outcomes. Klinicheskaya meditsina = Clinical medicine. 2014;92(12):64-72. (In Russ.).
  8. Natsional’noe rukovodstvo po glaukome dlya praktikuyushchikh vrachei, 3-e izd., isprav. i dop. Eds Egorov E.A., Astakhov Yu.S., Erichev V.P. M.: GEOTAR-Media; 2015. (In Russ.).
  9. Terminology and guidelines for glaucoma. 5th ed. Savona: Italy PubliComm; 2020.
  10. Dorofeev DA, Kryzhanovskaya AV, Ciganov AZ. Effectiveness of antihypertensive conservative-free therapy with fixed combination of bimatoprost and timolol (intermediate results). Vestnik oftal’mologii. 2020;136(2):73-80. (In Russ.). https://doi.org/10.17116/oftalma202013602173
  11. Dorofeev DA, Tur EV, Vizgalova LO, Tryapitsin ID, Ciganov AZ. The effect of preservative-free treatment of primary open-angle glaucoma on the state of ocular surface in combination therapy (intermediate results). Vestnik oftal’mologii. 2019;135(6):52-59. (In Russ.). https://doi.org/10.17116/oftalma201913506152
  12. Antonov AA, Karlova EV, Brezhnev AYu, Dorofeev DA. Current state of ophthalmic tonometry. Vestnik oftal’mologii. 2020;136(6):100-107. (In Russ.). https://doi.org/10.17116/oftalma2020136061100
  13. Brubaker RF. Delayed functional loss in glaucoma LII Edward Jackson Memorial Lecture. Am J Ophthalmol. 1996;121(5):473-483.  https://doi.org/10.1016/s0002-9394(14)75421-2
  14. Cockburn DM. Does reduction of intraocular pressure (IOP) prevent visual field loss in glaucoma. Optom Vis Sci. 1983;60(8):705-710.  https://doi.org/10.1097/00006324-198308000-00009
  15. Drange S, Anderson DR, Schulzer M. Risk factors for progression of visual field abnormalities in normal-tension glaucoma. Am J Ophthalmol. 2001; 131(6):699-708.  https://doi.org/10.1016/s0002-9394(01)00964-3
  16. Strakhov VV, Yartsev AV, Alekseev VV, Klimova ON, Kazanova SYu, Voronin NA. Structural and functional changes in the retinal layers in patients with primary glaucoma and possible means of retinoprotection. Vestnik oftal’mologii. 2019;135(2):70. (In Russ.). https://doi.org/10.17116/oftalma201913502170
  17. Strakhov VV, Egorov EA, Erichev VP, Yartsev AV, Petrov SYu, Dorofeev DA. The influence of long-term retinal protective therapy on glaucoma progression according to structural and functional tests. Vestnik oftal’mologii. 2020; 136(5):58-66. (In Russ.). https://doi.org/10.17116/oftalma202013605158
  18. Casson RJ. Possible role of excitotoxicity in the pathogenesis of glaucoma. Clin Exp Ophthalmol. 2006;34(1):54-63.  https://doi.org/10.1111/j.1442-9071.2006.01146.x
  19. Ko ML, Peng PH, Ma MC, Ritch R, Chen CF. Dynamic changes in reactive oxygen species and antioxidant levels in retinas in experimental glaucoma. Free Radic Biol Med. 2005;39(3):365-373.  https://doi.org/10.1016/j.freeradbiomed.2005.03.025
  20. Fahy ET, Chrysostomou V, Crowston JG. Impaired Axonal Transport and Glaucoma. Curr Eye Res. 2015;41(3):1-11.  https://doi.org/10.3109/02713683.2015.1037924
  21. Mozaffarieh M, Grieshaber MC, Flammer J. Oxygen and blood flow: Players in the pathogenesis of glaucoma. Mol Vis. 2008;14:224-233. 
  22. Lee S, Van Bergen NJ, Kong GY, et al. Mitochondrial dysfunction in glaucoma and emerging bioenergetic therapies. Exp Eye Res. 2011;93(2):204-212.  https://doi.org/10.1016/j.exer.2010.07.015
  23. Vandewalle E, Pinto LA, Olafsdottir OB, et al. Oximetry in glaucoma: Correlation of metabolic change with structural and functional damage. Acta Ophthalmol. 2014;92(2):105-110.  https://doi.org/10.1111/aos.12011
  24. Olafsdottir OB, Vandewalle E, Pinto LA, et al. Retinal oxygen metabolism in healthy subjects and glaucoma patients. Br J Ophthalmol. 2014;98(3):329-333.  https://doi.org/10.1136/bjophthalmol-2013-303162
  25. Olafsdottir OB, Hardarson SH, Gottfredsdottir MS, Harris A, Stefánsson E. Retinal oximetry in primary open-angle glaucoma. Investig Ophthalmol Vis Sci. 2011;52(9):6409-6413. https://doi.org/10.1167/iovs.10-6985
  26. Ekgardt VF, Dorofeev DA. Hemodynamic features in patients with simple and pseudoexfoliation primary open-angle glaucoma and ophthalmic hypertension. Part 2. Natsional’nyy zhurnal glaukoma = National Journal of Glaucoma. 2018;17(2):48-63 (In Russ.). https://doi.org/10.25700/NJG.2018.02.06
  27. Ekgardt VF, Dorofeev DA. The structural-functional and hemodynamic features in patients with simple and pseudoexfoliative open-angle glaucoma and ophthalmic hypertension in a model of glaucoma development prognosis. Part 3. Natsional’nyy zhurnal glaukoma = National Journal of Glaucoma. 2018;17(4):3-14 (In Russ.). https://doi.org/10.25700/NJG.2018.04.01
  28. Egorov EA, Erichev VP, Strakhov VV, et al. Structural and functional changes in the retina of patients with primary open-angle glaucoma and compensated intraocular pressure while undergoing retinoprotective therapy. Vestnik oftal’mologii. 2019;135(3):20. (In Russ.). https://doi.org/10.17116/oftalma201913503120

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.